This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

OKYO Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for OKYO Pharma.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	26.6%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

Nov 26

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

Jan 27

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Sep 22

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

Mar 17

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

Dec 02

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da OKYO Pharma jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

LSE:OKYO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-5	-4	-4	N/A
3/31/2022	N/A	-4	-4	-4	N/A
12/31/2021	N/A	-4	-3	-3	N/A
9/30/2021	N/A	-4	-3	-3	N/A
6/30/2021	N/A	-3	-2	-2	N/A
3/31/2021	N/A	-3	-1	-1	N/A
12/31/2020	N/A	-1	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-1	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-4	-2	-2	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-4	-2	-2	N/A
12/31/2018	N/A	-3	N/A	N/A	N/A
9/30/2018	N/A	-2	-2	-2	N/A
6/30/2018	N/A	-11	-1	-1	N/A
3/31/2018	N/A	-20	-1	-1	N/A
12/31/2017	N/A	-20	-1	-1	N/A
9/30/2017	N/A	-19	-1	-1	N/A
6/30/2017	N/A	-10	-1	-1	N/A
3/31/2017	N/A	0	-1	-1	N/A
12/31/2016	N/A	0	0	0	N/A
9/30/2016	N/A	0	0	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if OKYO's forecast earnings growth is above the savings rate (1.2%).

Ertrag vs. Markt: Insufficient data to determine if OKYO's earnings are forecast to grow faster than the UK market

Hohe Wachstumserträge: Insufficient data to determine if OKYO's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if OKYO's revenue is forecast to grow faster than the UK market.

Hohe Wachstumseinnahmen: Insufficient data to determine if OKYO's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if OKYO's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

OKYO Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

High number of new and inexperienced directors

High number of new and inexperienced directors

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

High number of new and inexperienced directors

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Independent Non-Executive Director Kunwar Shailubhai has left the company

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

OKYO Pharma Limited announced that it has received £5.437104 million in funding

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken